Comparative Study Between Ultrasound-Guided IPACK Block (Interspace Between the Popliteal Artery and the Posterior Capsule of the Knee) with Adductor Canal Block Versus Adductor Canal Block Alone for Postoperative Pain Management in Total Knee Arthroplasty
NCT ID: NCT06783712
Last Updated: 2025-01-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
60 participants
INTERVENTIONAL
2025-01-09
2025-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Adductor Canal Block With IPACK Versus Genicular Nerves Block With IPACK for Post-operative Analgesia
NCT07258277
Comparison of Pain Relief Post Knee Arthroscopy Using IPACK + Adductor Canal Block Vs. Adductor Canal Block Alone
NCT06265441
Comparison Between Two Blocks in Analgesia After Knee Arthroplasty
NCT07046377
A Comparative Study of Combined Adductor Canal and Interspace Between Popliteal Artery and Knee Capsule Versus Combined Adductor Canal and Genicular Nerve in Total Knee Arthroplasty
NCT06864663
Comparison Between (GNB) Combined With (IPACK) Block Versus ACB in TKA
NCT06423339
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All patients will undergo preoperative assessment (including full history, clinical examination \& routine preoperative laboratory investigations will be done (CBC, INR, PT, PTT, and blood chemistry like liver and kidney functions).
B.Intraoperative settings:
On arrival of the patients to the operative room, electrocardiography, non-invasive blood pressure, and pulse oximetry will be applied. Baseline parameters such as systolic blood pressure (SBP), diastolic blood pressure (DBP), mean blood pressure (MBP), heart rate (HR), and oxygen saturation (SpO2) will be recorded. An intravenous (IV) cannula will be inserted, and 500 cc lactated Ringer will be started intravenously as co-load volume. Premedication of 0.02mg/kg of midazolam IV will be given for sedation. Patients will receive spinal anesthesia by the supervisors of the research using the standard technique in a sitting position under complete aseptic conditions using betadine 10%. Then using 4ml lidocaine 2% for local skin infiltration, then introducing a spinal needle 25G (Mercury TM) till getting cerebrospinal fluid (CSF) flow. After getting the CSF flow 12.5mg of heavy bupivacaine 0.5% (Sunny Pharmaceutical Industries, Egypt) will be injected. Then the patient will lie supine with a slight inclination of the head, and then an assessment of the level of spinal anesthesia will be done using cold touch test.
Group I (Adductor canal group): Patients will receive the ultrasound-guided Adductor canal block (ACB) by the supervisors of the research performed just after skin closure. ACB will be performed under complete aseptic conditions. Using a high frequency (6-15MHz) linear probe of an ultrasound machine (Sonosite turbo M, Bothell, Washington, USA) covered with a sterile sheath and 100 mm needle SonoPlex (B-Braun Medical Inc., Bethlehem, PA, USA). ACB block will be performed while the patient is in a supine position at the point midway between the anterior superior iliac spine and the upper pole of the patella. The adductor canal will be located as a hyperechoic structure beneath the sartorius muscle, 100 mm needle SonoPlex will be advanced with the guidance of ultrasound in an in-plane technique and 20 ml bupivacaine (Marcaine) 0.25% will be injected.
Group II: The patients will receive ACB by the supervisors of the research just after skin closure as previously described in group I and then an IPACK block will be performed. IPACK block will be performed under complete aseptic precautions using the ultrasound machine with the high-frequency linear probe covered with a sterile sheath and 100 mm needle SonoPlex. IPACK block will be performed while the patient is in a supine position with slight knee flexion, the probe will be applied to the popliteal fossa for identification of the popliteal artery and femur. Then the probe will be distally slided for revealing the two femoral condyles followed by proximal sliding of the probe until the humps of the femoral condyles disappear and the flat metaphysis appear. A needle will be advanced from the lateral aspect and directed across the space between the popliteal artery and femur and once the needle reaches the medial edge of the femur, nearly at the level of the popliteal artery, negative aspiration is confirmed and 20 ml bupivacaine 0.25% will be injected incrementally as the needle is withdrawn.
C. postoperative settings Vital data including mean arterial blood pressure, heart rate, and oxygen saturation will be recorded 5 minutes before injection of each block and 5 minutes after injection and postoperatively at intervals of 1, 2, 4, 6, 12, 18 \& 24 hours. Postoperative pain will be evaluated by a Numeric Rating Scale for pain (NRS Pain) which is an 11-point scale divided as 0=no pain,1-3(mild pain), 4-7(moderate pain), and 7-10 (severe pain), 0-10 scale will be recorded every hour for the first 6 hours and every 2 hours for the rest of the first 24 hours. The time interval between the time of block injection and the time to the first rescue analgesia required (in case of NRS Pain score ≥4) will be measured. If the NRS Pain score is ≥4, patients will receive pethidine 30 mg IV. The total amount of analgesia that will be received in 24 hours postoperatively will be recorded. Assessing hemodynamic data and side effects such as nausea, vomiting, hypotension or hematoma at site of injection.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group I: Adductor canal block alone
Adductor canal block
Group I: Patients will receive the ultrasound-guided Adductor canal block (ACB) by the supervisors of the research performed just after skin closure. ACB will be performed under complete aseptic conditions. Using a high frequency (6-15MHz) linear probe of an ultrasound machine (Sonosite turbo M, Bothell, Washington, USA) covered with a sterile sheath and 100 mm needle SonoPlex (B-Braun Medical Inc., Bethlehem, PA, USA). ACB block will be performed while the patient is in a supine position at the point midway between the anterior superior iliac spine and the upper pole of the patella. The adductor canal will be located as a hyperechoic structure beneath the sartorius muscle, 100 mm needle SonoPlex will be advanced with the guidance of ultrasound in an in-plane technique and 20 ml bupivacaine (Marcaine) 0.25% will be injected.
Group II: IPACK block with Adductor canal block
Adductor Canal Block (ACB) + iPACK Block
Group II: The patients will receive ACB by the supervisors of the research just after skin closure as previously described in group I and then an IPACK block will be performed. IPACK block will be performed under complete aseptic precautions using the ultrasound machine with the high-frequency linear probe covered with a sterile sheath and 100 mm needle SonoPlex. IPACK block will be performed while the patient is in a supine position with slight knee flexion, the probe will be applied to the popliteal fossa for identification of the popliteal artery and femur. Then the probe will be distally slided for revealing the two femoral condyles followed by proximal sliding of the probe until the humps of the femoral condyles disappear and the flat metaphysis appear. A needle will be advanced from the lateral aspect and directed across the space between the popliteal artery and femur and once the needle reaches the medial edge of the femur,20 ml bupivacaine 0.25% will be injected incrementally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Adductor canal block
Group I: Patients will receive the ultrasound-guided Adductor canal block (ACB) by the supervisors of the research performed just after skin closure. ACB will be performed under complete aseptic conditions. Using a high frequency (6-15MHz) linear probe of an ultrasound machine (Sonosite turbo M, Bothell, Washington, USA) covered with a sterile sheath and 100 mm needle SonoPlex (B-Braun Medical Inc., Bethlehem, PA, USA). ACB block will be performed while the patient is in a supine position at the point midway between the anterior superior iliac spine and the upper pole of the patella. The adductor canal will be located as a hyperechoic structure beneath the sartorius muscle, 100 mm needle SonoPlex will be advanced with the guidance of ultrasound in an in-plane technique and 20 ml bupivacaine (Marcaine) 0.25% will be injected.
Adductor Canal Block (ACB) + iPACK Block
Group II: The patients will receive ACB by the supervisors of the research just after skin closure as previously described in group I and then an IPACK block will be performed. IPACK block will be performed under complete aseptic precautions using the ultrasound machine with the high-frequency linear probe covered with a sterile sheath and 100 mm needle SonoPlex. IPACK block will be performed while the patient is in a supine position with slight knee flexion, the probe will be applied to the popliteal fossa for identification of the popliteal artery and femur. Then the probe will be distally slided for revealing the two femoral condyles followed by proximal sliding of the probe until the humps of the femoral condyles disappear and the flat metaphysis appear. A needle will be advanced from the lateral aspect and directed across the space between the popliteal artery and femur and once the needle reaches the medial edge of the femur,20 ml bupivacaine 0.25% will be injected incrementally
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Previously known allergy to one of the drugs being used in the study.
* Physical status: ASA grades more than III
* History or evidence of coagulopathy, use of anti-coagulant or anti-platelet therapy.
* Patients with neuromuscular disorders
* Injection site infection.
20 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hager Talal Mohamed, MBBCH
Role: PRINCIPAL_INVESTIGATOR
Anesthesia Resident Ain Shams University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain Shams University
Cairo, Egypt, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Hager Talal Mohamed, MBBCH
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FMASU MS47/2024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.